Canaccord lowered the firm’s price target on Definitive Healthcare (DH) to $3 from $4 and keeps a Hold rating on the shares. The firm said they reported Q4 results that were at or above the high-end of guidance ranges on both the top- and bottom-line, but growth remains challenged.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DH: